Skip to content

Study · Animal study (in vivo) · rat · 2025

1 result

Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency.

Xu H, Liu M, Jia X, Zhao S, Xia Y, Lu B, Yang F, Wang S, Jin L

Journal of medicinal chemistry16 Mar 2025Cited by 1 (Europe PMC)

PMID40091212 (opens in a new tab)DOI10.1021/acs.jmedchem.5c00217 (opens in a new tab)PepBankPUB-40091212
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, ibutamoren at 10 mg/kg stimulated GH release with lower potency than compound 4b at 0.1 mg/kg.

    In plain wordsIn rats, ibutamoren was less potent than compound 4b at stimulating natural growth hormone release.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseGH release potency
    Study

    ratsn: not reported in source

    Comparator
    compound 4b
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg/kg · oralAs given in this study (rats).

    Source sentences

    Summary
    Starting from capromorelin, we designed, synthesized, and characterized a novel orally active GHSR-1a agonist, compound 4b (hGHSR-1a EC50 = 0.49 nM), which effectively stimulates endogenous GH release in rats at oral doses as low as 0.1 mg/kg─100-fold more potent than ibutamoren (10 mg/kg).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.